Ann: Encouraging data from 2nd dose cohort in CLTX CAR T trial, page-4

Good stuff! These phase I's are designed for safety and that box is ticked. Any stable disease at this stage of the game is great news especially so soon after infusion.

We have seen in the recent articles how in Car-T therapies, the cells have an ability to remain persistent and active. By the time the conference comes around they will have worked more of their magic and as Stockrock says we may see the response move in to partial or complete. We may also get updates again before the conference when these milestones are achieved.

Stockrock you have been quiet there, probably too busy scooping up more shares...

The future is looking bright

Solid Management - Check

Solids Assets - Check

IP/patent’s secured - Check

Growing diverse pipeline - Check

Huge M & A’s in this field - Check

Relationships w key medical institutions- Check

Inventors of assets in top20 SH - Check

Addressing huge unmet need w no SOC- Check

Founder and Chairman who have done it all before - Check

CEO who has done it before with Kite- Check

Founder and Chairman with another $3b MC (was) ASX company - Check

Management buying shares on market - Check

Multiple Stockbroker valuations over $1 (which only include the assets in clinic) - Check